Blood transfusions
Transfusion-associated transmission (TAT) of West Nile virus was first recognized in the United States, in 2002. This prompted the rapid development of two nucleic acid testing (NAT) assays to screen donated blood for WNV viremia. By July 14, 2004, all blood banks in the United States had implemented testing.
FDA recommends screening year-round for WNV using a licensed minipool nucleic acid-amplification testing (MP-NAT) or individual donation NAT (ID-NAT) on donor samples of whole blood and blood components (FDA 2008). Because of the dilution effect inherent in screening by MP-NAT, this method is less sensitive than ID-NAT. FDA further recommends that blood centers using MP-NAT screening establish criteria to switch to ID-NAT during periods of high WNV activity in their geographic area of collection.
Questions frequently ask by patients
West Nile Virus Disease Cases and Presumptive Viremic Blood Donors by State – United States, 2022 (as of January 10, 2023) | |||||
State |
Neuroinvasive Disease Cases† |
Non–neuroinvasive Disease Cases |
Total cases |
Deaths |
Presumptive viremic blood donors‡ |
Alabama |
3 |
2 |
5 |
0 |
1 |
Arizona |
47 |
15 |
62 |
4 |
6 |
Arkansas |
2 |
3 |
5 |
1 |
0 |
California |
129 |
39 |
168 |
11 |
20 |
Colorado |
129 |
75 |
204 |
18 |
16 |
Connecticut |
7 |
0 |
7 |
0 |
0 |
Delaware |
1 |
0 |
1 |
0 |
0 |
District of Columbia |
1 |
0 |
1 |
0 |
0 |
Florida |
5 |
0 |
5 |
0 |
0 |
Georgia |
15 |
3 |
18 |
2 |
4 |
Idaho |
1 |
2 |
3 |
0 |
0 |
Illinois |
23 |
7 |
30 |
4 |
2 |
Indiana |
6 |
0 |
6 |
0 |
2 |
Iowa |
8 |
1 |
9 |
0 |
11 |
Kansas |
6 |
8 |
14 |
0 |
7 |
Kentucky |
2 |
2 |
4 |
1 |
0 |
Louisiana |
40 |
7 |
47 |
6 |
5 |
Maryland |
3 |
1 |
4 |
1 |
1 |
Massachusetts |
7 |
1 |
8 |
1 |
0 |
Minnesota |
15 |
4 |
19 |
1 |
2 |
Mississippi |
4 |
1 |
5 |
1 |
0 |
Missouri |
11 |
2 |
13 |
2 |
0 |
Nebraska |
37 |
27 |
64 |
4 |
24 |
New Jersey |
12 |
7 |
19 |
3 |
2 |
New Mexico |
8 |
3 |
11 |
1 |
3 |
New York |
66 |
13 |
79 |
3 |
7 |
North Carolina |
10 |
0 |
10 |
1 |
7 |
North Dakota |
8 |
18 |
26 |
0 |
10 |
Ohio |
5 |
2 |
7 |
1 |
2 |
Oklahoma |
2 |
0 |
2 |
1 |
1 |
Oregon |
0 |
5 |
5 |
0 |
0 |
Pennsylvania |
26 |
8 |
34 |
2 |
6 |
Rhode Island |
1 |
0 |
1 |
0 |
0 |
South Carolina |
9 |
1 |
10 |
1 |
9 |
South Dakota |
35 |
31 |
66 |
1 |
12 |
Tennessee |
2 |
3 |
5 |
0 |
1 |
Texas |
31 |
5 |
36 |
7 |
12 |
Utah |
5 |
0 |
5 |
0 |
0 |
Virginia |
5 |
0 |
5 |
1 |
0 |
Washington |
3 |
1 |
4 |
0 |
1 |
Wisconsin |
5 |
0 |
5 |
0 |
1 |
Wyoming |
2 |
1 |
3 |
0 |
0 |
Totals |
737 |
298 |
1,035 |
79 |
175 |
Source: CDC West Nile Virus Home Statistics & Maps Preliminary Maps & Data for 2022. Accessed From: https://www.cdc.gov/westnile/statsmaps/preliminarymapsdata2022/disease-cases-state-2022.html |
Instant feedback:
CDC. West Nile Virus Home. Frequently Asked Questions. Retreived 11/3/17. https://www.cdc.gov/westnile/faq/blood.html
Food and Drug Administration. Guidance for industry: use of nucleic acid tests to reduce the risk of transmission of West Nile virus from donors of whole blood and blood components intended for transfusion. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2008.